IP Library Granted Patent US 8,986,971
Granted Patent B2
US 8,986,971 · App. 11/860,491 · Granted Mar 24, 2015

Salt formulations for the fermentation of marine microorganisms

Inventors: Kin Sing Lam (San Diego, CA); Ginger Tsueng (San Diego, CA)
Assignee: Triphase Research and Development I Corp.
C12N1/20C12P17/188Y10S435/822
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,986,971
App. No.
11/860,491
Granted
Mar 24, 2015
Kind
B2
Abstract

Growth medium are disclosed for use in fermenting a marine microorganism. The medium comprise Potassium, Calcium, Strontium, Borate and Fluoride at specific concentrations. Alternatively, the growth medium comprises cobalt at specified concentrations or comprises vitamin B 12 at specified concentrations. Methods of producing certain desired compound by fermentation of a marine microorganism are also disclosed.

Claims (61)

1. A method of fermenting a Salinospora microorganism, the method comprising:

(a) obtaining a fermentation medium comprising:

KCl concentration between 400 mg/L and 1 g/L,

MgSO 4 concentration between 2 g/L and 6 g/L,

CaCl concentration between 200 mg/L and 700 mg/L,

SrCl 2 concentration between 5 mg/L and 50 mg/L,

H 3 BO 3 concentration between 10 mg/L and 50 mg/L,

NaF concentration between 1 mg/L and 5 mg/L,

a carbon source,

a nitrogen source,

cobalt ion concentration between 0.2μMole/L and 2.0μMole/L, and

at least one of the following: NaCl at a concentration between 5 g/L and 30 g/L, Na 2 SO 4 at a concentration between 10 g/L and 40 g/L, and KCl at a concentration between 25 g/L and 35 g/L;

(b) inoculating the fermentation medium with the microorganism; and

(c) culturing the microorganism in the fermentation medium.

2. The method of claim 1 , wherein the fermentation medium comprises cobalt ion at a concentration between 0.2 μMole/L and 0.5 μMole/L.

3. The method of claim 1 , wherein the fermentation medium comprises cobalt ion at a concentration between 1.1 μMole/L and 1.9 μMole/L.

4. The method of claim 1 , wherein the fermentation medium comprises cobalt ion at a concentration between 0.4 μMole/L and 2 μMole/L.

5. The method of claim 1 , wherein the fermentation medium comprises NaCl at a concentration between 5 g/L and 30 g/L.

6. The method of claim 1 , wherein after step (a) the fermentation medium comprises sulfate species at a concentration between 0.07 M and 0.28 M.

7. The method of claim 1 , wherein the fermentation medium comprises NaCl and Na 2 SO 4 .

8. The method of claim 1 , wherein obtaining the fermentation medium comprises dissolving a salt formulation in water, wherein the salt formulation comprises:

KCl at a mass percent between 90% and 75%,

MgSO 4 at a mass percent between 20% and 5%,

CaClhd 2 at a mass percent between 5% and 3%,

SrClhd 2 at a mass percent between 0.3% and 0.03%,

H 3 BO 3 at a mass percent between 0.4% and 0.04%, and

NaF at a mass percent between 0.03% and 0.01%.

9. The method of claim 1 , wherein the fermentation medium comprises CoCl 2 .

10. The method of claim 9 , wherein the concentration of CoCl 2 is between 30 μg/L and 70μg/L.

11. The method of claim 9 , wherein the concentration of CoCl 2 is between 150 μg/L and 250 g/L.

12. The method of claim 1 , wherein the microorganism is capable of producing Salinosporamide A.

13. The method of claim 1 , comprising adding a resin to the fermentation medium.

14. The method of claim 13 , wherein the resin is added before 96 hours after step (b).

15. The method of claim 13 , wherein the resin is added before 24 hours after step (b).

16. The method of claim 13 , wherein the resin is added before step (b).

17. The method of claim 13 , wherein the resin is an adsorption resin.

18. The method of claim 13 , wherein the resin is a hydrophobic adsorption resin.

19. The method of claim 13 , wherein the resin includes at least one resin selected from the group consisting of Amberlite XAD2, Amberlite XAD4, Amberlite XAD7, Amberlite XAD7HP, Amberlite XAD16, Amberlite XAD761, Amberlite XAD 761, Amberlite XAD1180, Diaion HP2MG, Diaion HP20, Diaion HP21, Sepabeads SP825, Sepabeads SP850, Sepabeads SP70, Sepabeads SP700, and Sepabeads SP207.

20. The method of claim 13 , wherein the resin includes at least one resin selected from the group consisting of Amberlite XAD2, Amberlite XAD4, Amberlite XAD7, Amberlite XAD7HP and Amberlite XAD16.

21. The method of claim 13 , wherein the resin is Amberlite XAD7.

22. The method of claim 13 , wherein the fermentation medium comprises a ratio of resin to total nitrogen of 5:1 to 100:1.

23. The method of claim 13 , wherein the fermentation medium comprises a ratio of resin to total nitrogen of 20:1 to 40:1.

24. The method of claim 13 , wherein the resin is added in more than one portion.

25. The method of claim 1 , wherein the microorganism is Salinispora tropica.

26. The method of claim 1 , wherein the microorganism is Salinispora tropica NPS021184.

27. A method of fermenting a Salinospora tropica microorganism, the method comprising:

obtaining a medium comprising:

a carbon source,

a nitrogen source,

CaCO 3 concentration between 10 mg/L and 5 g/L,

Fe 2 (SO 4 ) 3 concentration between 5 mg/L and 1 g/L,

KBr concentration between 5 mg/L and 400 mg/L,

KCl concentration between 400 mg/L and 1 g/L

CaCl 2 concentration between 200 mg/L and 700 mg/L,

SrCl 2 concentration between 5 mg/L and 50 mg/L,

H 3 BO 3 concentration between 10 mg/L and 50 mg/L,

NaF concentration between 1 mg/L and 5 mg/L,

CoCl 2 concentration between 52 μg/L and 208 μg/L, and

at least one of the following: NaCl at a concentration between 5 g/L and 30 g/L, and Na 2 SO 4 at a concentration between 10 g/L and 40 g/L;

inoculating said medium with said microorganism; and

culturing said microorganism in said medium.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2024
From: 1096271 B.C. UNLIMITED LIABILITY COMPANY
To: CELGENE TRI A HOLDINGS LTD.
Reel/Frame 067256/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2024
From: CELGENE TRI A HOLDINGS LTD.
To: CELGENE INTERNATIONAL II SARL
Reel/Frame 067256/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2024
From: CELGENE RESEARCH AND DEVELOPMENT I ULC, FORMERLY KNOWN AS TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
To: 1096271 B.C. UNLIMITED LIABILITY COMPANY
Reel/Frame 067256/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2017
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 041698/0404 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2016
From: HBM VIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCARDERO PARTNER II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 040327/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2013
From: NEREUS PHARMACEUTICALS, INC.
To: TRIPHASE RESEARCH AND DEVELOPMENT I CORP.
Reel/Frame 029899/0101 →
SECURITY AGREEMENT Recorded May 21, 2009
From: NEREUS PHARMACEUTICALS, INC.
To: HBM BIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCADERO PARTNERS II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
Reel/Frame 022719/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2008
From: LAM, KIN SING; TSUENG, GINGER
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 020529/0853 →
Continuity (5)
Provisional Application 60846774 · Sep 22, 2006
Provisional Application 60949147 · Jul 11, 2007
Provisional Application 60952368 · Jul 27, 2007
Provisional Application 60952349 · Jul 27, 2007
Related Publication 20080160590A1 · Jul 3, 2008